NCT05070312

Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants

A Phase I, Randomized, Double-blind, Placebo-controlled, Dose-ascending Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of MEDI3506 in Healthy Chinese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is to evaluate the pharmacokinetics, immunogenicity, safety and tolerability of investigational drug MEDI3506 with single dose in Healthy Chinese participants.

Detailed description

A phase I, randomised, double-blind, placebo-controlled parallel-group study to evaluate the pharmacokinetics, immunogenicity, safety, and tolerability of single dose of MEDI3506 in healthy Chinese Participants

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
BIOLOGICAL	MEDI3506	MEDI3506
DRUG	Placebo	Placebo

Timeline

• Start date: 2021-08-23
• Primary completion: 2022-02-07
• Completion: 2022-02-07
• First posted: 2021-10-07
• Last updated: 2022-03-25

Locations

1 site across 1 country: China